Background: Limited attention is directed to the potential conflicts of interest (COI) of the authors of practice guidelines writing groups of professional medical societies (PMS) and industry. The objective of this study was to report the proportion of authors with potential COI among guidelines writing groups of PMS.
Methods: A systematic search in PubMed to identify practice guidelines of a convenience sample of 12 publicly known PMS for a period of 3 years. The authors’ disclosures of COI were reviewed for the identified guidelines.
Results: We identified 126 guidelines, of which 107 (85%) reported authors’ disclosures of COI and 19 (15%) did not. With the exception of the US Preventive Services Task Force, all of the reviewed guidelines writing groups of PMS had potential COI to some extent. The maximum percentage of authors with potential COI varied among PMS from 25% to 100%.
Conclusions: A substantial variation of percentage of authors with potential COI exists among guidelines writing groups of different PMS. Several practice guidelines of PMS fail to include the disclosures of potential COI in their published guidelines. We made several suggestions to promote the transparency of potential COI in clinical practice guidelines.
1. Chimonas S, Rothman DJ. New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation. Health Aff (Millwood) 2005; 24: 949–960.
2. Morris L, Taitsman JK. The agenda for continuing medical education—limiting industry’s influence. N Engl J Med 2009; 361: 2478–2482.
4. Drucker J. Beyond conflict of interest: maybe wrong questions are being asked. BMJ 2004; 329: 686.
5. Avraham R. Clinical practice guidelines: the warped incentives in the U.S. healthcare system. Am J Law Med 2011; 37: 7–40.
6. Nissen SE. Can we trust cardiovascular practice guidelines? Comment on “Conflicts of interest in cardiovascular clinical practice guidelines.” Arch Intern Med 2011; 171: 584–585.
7. Scott IA, Guyatt GH. Clinical practice guidelines: the need for greater transparency in formulating recommendations. Med J Aust 2011; 195: 29–33.
9. Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009; 301: 1367–1372.
12. Mendelson TB, Meltzer M, Campbell EG, et al. Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med 2011; 171: 577–584.
13. Baumann MH, Lewis SZ, Gutterman D. ACCP evidence-based guideline development: a successful and transparent approach addressing conflict of interest, funding, and patient-centered recommendations. Chest 2007; 132: 1015–1024.
14. Schunemann HJ, Osborne M, Moss J, et al. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med 2009; 180: 564–580.
15. Wood S. Studies linking drug-eluting stents to increased mortality/MI spark impassioned pleas for reason and calls for calm. http://www.theheart.org/article/736863.do
. Published September 3, 2006. Accessed June 10, 2011.
16. Thomas M. Interventional cardiology and the medical devices industry: is there a conflict of interest? Heart 2007; 93: 1351–1352.
17. Camilleri M, Parke DW 2nd. Perspective: conflict of interest and professional organizations: considerations and recommendations. Acad Med 2010; 85: 85–91.
18. McCrary SV, Anderson CB, Jakovljevic J, et al. A national survey of policies on disclosure of conflicts of interest in biomedical research. N Engl J Med 2000; 343: 1621–1626.
19. Clark J, Gonzalez J, Mansi B, et al. Enhancing transparency and efficiency in reporting industry-sponsored clinical research: report from the Medical Publishing Insights and Practices initiative. Int J Clin Pract 2010; 64: 1028–1033.
21. White PF. Consensus guidelines for managing postoperative nausea and vomiting: is there a conflict of interest? Anesth Analg 2004; 98: 550–551.
22. Edwards IR. Conflicts of interest in medicines safety and regulation: how much conflict and how much interest should we allow? Drug Saf 2011; 34: 617–621.
23. Okike K, Kocher MS, Wei EX, et al. Accuracy of conflict-of-interest disclosures reported by physicians. N Engl J Med 2009; 361: 1466–1474.
24. Psaty BM. Conflict of interest, disclosure, and trial reports. JAMA 2009; 301: 1477–1479.
25. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001; 110: 551–557.
26. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003; 290: 252–255.
27. Aron D, Pogach L. Transparency standards for diabetes performance measures. JAMA 2009; 301: 210–212.
28. Ferris LE, Fletcher RH. Conflict of interest in peer-reviewed medical journals: the World Association of Medical Editors (WAME) position on a challenging problem. Neurosurgery 2010; 66: 629–630.